News
ENGNW
0.2101
-19.63%
-0.0513
enGene Holdings Is Maintained at Neutral by UBS
Dow Jones · 2d ago
enGene Holdings Price Target Cut to $2.00/Share From $9.00 by UBS
Dow Jones · 2d ago
enGene price target lowered to $2 from $9 at UBS
TipRanks · 2d ago
ENGENE THERAPEUTICS INC <ENGN.O>: UBS CUTS TARGET PRICE TO $2 FROM $9
Reuters · 2d ago
Weekly Report: what happened at ENGN last week (0504-0508)?
Weekly Report · 5d ago
enGene Therapeutics announces annual shareholder meeting webcast
PUBT · 05/08 20:08
Leerink downgraded enGene to Market Perform following LEGEND update
TipRanks · 05/08 18:32
enGene downgraded to Perform from Outperform at Oppenheimer
TipRanks · 05/08 16:22
Why Is enGene Therapeutics Stock Falling Friday?
Benzinga · 05/08 15:34
enGene Holdings Cut to Market Perform From Market Outperform by Citizens
Dow Jones · 05/08 14:56
Citizens Downgrades enGene Therapeutics to Market Perform
Benzinga · 05/08 14:46
enGene Holdings Cut to Neutral From Buy by Guggenheim
Dow Jones · 05/08 13:01
Guggenheim Downgrades enGene Therapeutics to Neutral
Benzinga · 05/08 12:51
enGene Holdings Cut to Equal-Weight From Overweight by Wells Fargo
Dow Jones · 05/08 12:38
enGene Holdings Price Target Cut to $2.00/Share From $25.00 by Wells Fargo
Dow Jones · 05/08 12:38
Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2
Benzinga · 05/08 12:29
enGene downgraded to Market Perform from Outperform at Leerink
TipRanks · 05/08 12:11
enGene Holdings Price Target Cut to $6.00/Share From $25.00 by HC Wainwright & Co.
Dow Jones · 05/08 11:29
enGene Holdings Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/08 11:29
HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $6
Benzinga · 05/08 11:19
More
Webull provides a variety of real-time ENGNW stock news. You can receive the latest news about enGene Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENGNW
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.